374 related articles for article (PubMed ID: 4053067)
21. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
[TBL] [Abstract][Full Text] [Related]
22. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
Liliemark JO; Plunkett W
Cancer Res; 1986 Mar; 46(3):1079-83. PubMed ID: 3484676
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Paul CY; Gahrton CG; Peterson CO
Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
[TBL] [Abstract][Full Text] [Related]
24. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Liliemark JO; Gahrton G; Paul CY; Peterson CO
Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
[TBL] [Abstract][Full Text] [Related]
25. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
26. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
27. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
28. A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
Yamauchi T; Ueda T; Nakamura T
Cancer Res; 1996 Apr; 56(8):1800-4. PubMed ID: 8620496
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
30. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
31. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
32. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Gandhi V; Du M; Kantarjian HM; Plunkett W
Leukemia; 1994 Sep; 8(9):1463-8. PubMed ID: 8090026
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
Chou TC; Hutchinson DJ; Schmid FA; Philips FS
Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
[TBL] [Abstract][Full Text] [Related]
34. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
Kishi S; Goto N; Nakamura T; Ueda T
Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologically directed ara-C therapy for refractory leukemia.
Plunkett W; Iacoboni S; Estey E; Danhauser L; Liliemark JO; Keating MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):20-30. PubMed ID: 4012338
[TBL] [Abstract][Full Text] [Related]
37. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Estey EH; Keating MJ; McCredie KB; Freireich EJ; Plunkett W
Leukemia; 1990 Feb; 4(2):95-9. PubMed ID: 2304361
[TBL] [Abstract][Full Text] [Related]
38. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
[TBL] [Abstract][Full Text] [Related]
39. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
40. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.
Zittoun R; Zittoun J; Marquet J; Rustum Y; Creaven P
Cancer Res; 1985 Oct; 45(10):5186-92. PubMed ID: 4027995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
